Cost Per Point Reduction in LDL-C for Patients Treated with Evolocumab 140 mg or Alirocumab 75/150 mg Within Employer-Sponsored Insurance Plans

Cost Per Effectively Treated Patient with Evolocumab 140 mg and Alirocumab 75/150 mg

Cost-Effectiveness of OnabotulinumtoxinA for Chronic Migraine Prophylaxis in Adults in the United States

Cost Per Effectively Treated Patient With Evolocumab 140mg, Alirocumab 75/150mg Among Patients Using PCSK9 Inhibitor Therapy (requires purchase)

Estimating the cost per percent point reduction in LDL-C for patients treated with PCSK9 inhibitors in a large national health plan